(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 7.73% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Amneal Pharmaceuticals's revenue in 2025 is $2,793,957,000.On average, 3 Wall Street analysts forecast AMRX's revenue for 2025 to be $938,222,549,155, with the lowest AMRX revenue forecast at $930,177,992,707, and the highest AMRX revenue forecast at $945,319,848,465. On average, 3 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,003,835,294,319, with the lowest AMRX revenue forecast at $971,186,539,621, and the highest AMRX revenue forecast at $1,025,244,669,492.
In 2027, AMRX is forecast to generate $1,073,489,380,637 in revenue, with the lowest revenue forecast at $1,022,671,948,861 and the highest revenue forecast at $1,124,306,812,412.